Trevi Therapeutics (TRVI)Trevi Therapeutics, Inc.BATS:TRVIKalaGhaziTrevi Therapeutics has seen its share price trace a dramatic path in recent years, and that volatility naturally raises a straightforward question for investors who focus on balance-sheet fundamentals: is the latest share price actually grounded in what the company’s book value can support? In other words, how much of the stock’s current valuation is backed by the net assets reported on its books, and how much reflects expectations about future prospects rather than present accounting value? Over the past five years, Trevi Therapeutics has delivered a very large share price gain. For anyone holding the stock today, that raises a follow-up question: how much of that move is genuinely supported by the net assets on the company’s balance sheet? A stock can rise sharply for reasons that are not directly tied to book value—such as clinical progress, pipeline expectations, or changes in investor sentiment—so the relationship between price and book value can become strained over time. Investors who care about balance-sheet support therefore need to consider whether the current price is justified by the company’s reported net assets or by other factors. Part of the complication is the company’s business model. Trevi Therapeutics relies heavily on funding research and development through equity and potentially other capital sources. That reliance can shift how closely the stock price tracks reported book value over time. When a company raises capital by issuing equity, book value may change, and the number of shares outstanding can increase, which affects per-share book value. At the same time, spending on research and development can reduce reported book value even as it potentially adds to the company’s longer-term prospects. As a result, the stock price and book value may diverge, and the gap between them can widen or narrow depending on financing activity, spending, and investor expectations. For investors, the key issue is not simply whether the stock has risen a lot, but whether the current valuation is supported by the company’s net assets or by assumptions about future success. A stock that looks expensive against book value may still be justified if the company’s prospects are strong, but that requires a clear understanding of what book value represents and how the company’s financing model affects it. The question is especially relevant for a business that funds research and development through equity, because changes in capital structure can influence both reported book value and the share count used to calculate per-share metrics.